Johnson & Johnson Reports Q1 2023 Results
New Brunswick, N.J. (April 18, 2023) – Johnson & Johnson (NYSE: JNJ) today announced results for first-quarter 2023. “Our first quarter results demonstrate strong performance across all three segments of our business and reflect the dedication of Johnson & Johnson colleagues around the world,” said Joaquin Duato, Chairman of the Board and Chief Executive Officer. “With this momentum, I look forward to the remainder of the year, one filled with exciting catalysts that will create both near- and long-term value for patients and all of our stakeholders.”OVERALL FINANCIAL RESULTSQ1($ in Millions, except EPS)20232022% ChangeReported Sales$24,746$23,4265.6%Net Earnings/(Loss)($68)$5,149(101.3)%EPS (basic/diluted) 5($0.03)$1.93(101.6)%Q1Non-GAAP* ($ in Millions, except EPS)20232022% ChangeOperational Sales1,29.0%Adjusted Operational Sales1,37.6%Adjusted Net Earnings1,4$7,068$7,129(0.9)%Adjusted EPS (diluted)1,4$2.68$2.670.4% 1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules 2 Excludes the impact of translational currency 3 Excludes the net impact of acquisitions and divestitures and translational currency 4 Excludes intangible amortization expense and special items 5 Basic shares are used to calculate loss per share as use of diluted shares when in a loss position would be anti-dilutiveNote: values may have been roundedREGIONAL SALES RESULTSQ1% Change($ in Millions)...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Financial Source Type: news
More News: Abiraterone Acetate | Babies | Babies Heart Conditions | Bladder Cancer | Cancer | Cancer & Oncology | Cancer Vaccines | Cardiology | Cialis | Conferences | Covid Vaccine | COVID-19 | Environmental Health | Food and Drug Administration (FDA) | Genetics | Government | Health Management | Heart | Hypertension | Ibuprofen | Immunotherapy | Imodium | Inflammatory Bowel Disease | Legislation | Loperamide | Lung Cancer | Myeloma | New Drug Applications | Non-Small Cell Lung Cancer | Oral Cancer | Orthopaedics | Pharmaceuticals | Podcasts | Prednisolone | Prednisone | Pregnancy | Profits and Losses | Prostate Cancer | Remicade | Respiratory Medicine | SARS | Science | Skin | Smokers | Stelara | Strategic Planning | Study | Surgery | Vaccines | Websites